Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. New product approvals, like Niktimvo, should diversify Incyte's revenue and reduce reliance on Jakafi. The EPS miss is mostly related to elevated R&D spending, which will be critical to ease investors' fears about a potential loss of revenue from Jakafi in the coming years.
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
On Tuesday, Incyte Corporation INCY reported third-quarter revenue of $1.14 billion, up 24% year over year, beating the consensus of $1.08 billion.
Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q3 2024 Results Conference Call October 29, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Steven Stein - Chief Medical Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Barry Flannelly - General Manager, North America Conference Call Participants Michael Schmidt - Guggenheim Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Matt Phipps - William Blair James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Derek Archila - Wells Fargo David Lebowitz - Citibank Marc Frahm - TD Cowen Brian Abrahams - RBC Capital Markets Andy Chen - Wolfe Research Jay Olson - Oppenheimer Gavin Clark-Gartner - Evercore ISI Evan Seigerman - BMO Capital Markets Tazeen Ahmad - Bank of America Srikripa Devarakonda - Truist Securities Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Incyte Third Quarter Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
On Tuesday, Incyte Corporation INCY reported third-quarter revenue of $1.14 billion, up 24% year over year and beating the consensus of $1.08 billion.
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
Incyte reports mixed third-quarter results as earnings miss estimates while revenues beat the same due to increased sales of Jakafi and Opzelura.
Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Incyte raises 2024 sales forecast for top-selling drug Jakafi
Incyte beat Wall Street estimates for third-quarter revenue and raised annual sales forecast for its top-selling drug on Tuesday, as uptake among patients remained strong.
Incyte (INCY) Q3 Earnings Miss Estimates
Incyte (INCY) came out with quarterly earnings of $1.07 per share, missing the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.10 per share a year ago.
Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
INCY's third-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Truist Securities has downgraded Incyte Corporation INCY, noting Jakafi's (ruxolitinib) patent loss approaching in 2028.
Incyte Announces Promising New Data on Oncology Candidate at ESMO
INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.
